7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-07-22 2012-12-31 2012-07-22 2011-07-22 2011-03-31 2010-07-22 2008-06-30 2007-07-22 2006-07-22 2005-07-22 2004-03-31 2003-12-31 2003-07-22 2002-07-22 2001-12-31 2001-07-22 
      
    		                                                                
      cash flows from operating activities:
    		                                                                
      net income
    		-179,947,000 196,892,000 -447,508,000 159,049,000 33,611,000 6,460,000 36,119,000 45,655,000 -40,937,000 -23,940,000 -516,755,000 -109,244,000 -257,738,000 -231,481,000 -105,025,000 -121,981,000 -48,144,000 -81,405,000 -167,250,000 -189,317,000 -196,499,000 -150,820,000 -17,492,000 -235,703,000 -126,326,000 -276,403,000 -76,643,000 -140,895,000 -76,393,000 -109,267,000 -35,363,000 -23,998,000 -47,734,000 -63,046,000 84,090,000 -88,452,000 -56,742,000 -62,301,000 -59,770,000 -64,681,000 -51,939,000 -41,851,000 -61,559,000 -44,416,000 -29,226,000 -33,874,000 -28,273,000 -440,071,000 -42,084,000 -372,031,000 -17,704,000 308,925,000 -305,813,000 -584,000 -7,042,123 -9,722,975 -9,061,150 -5,499,179 -7,532,512 113,481,830 -3,418,817 -95,035,100 -64,898,088 -63,472,543 
      adjustments to reconcile net income to net cash flow from operating activities
    		                                                                
      loss on debt extinguishment
    		       0 0 0 387,329,000 0                                                     
      stock-based compensation
    		14,927,000 37,025,000 41,428,000 49,676,000 43,450,000 50,482,000 40,692,000 45,826,000 48,061,000 47,377,000 41,250,000 50,510,000 50,418,000 102,892,000 29,198,000 29,782,000 26,684,000 28,969,000 28,508,000 29,527,000 26,903,000 27,616,000 24,024,000 22,064,000 20,637,000 19,762,000 16,139,000 12,838,000 11,484,000 15,279,000 10,526,000 7,366,000 6,922,000 10,465,000 5,712,000 6,869,000 9,428,000 6,830,000 6,835,000 6,348,000 5,683,000 5,930,000 14,156,000 5,767,000 4,649,000 5,587,000 4,342,000 35,724,000 1,671,000 30,233,000 708,000 -25,149,000 27,011,000 426,000 -260,433 2,360,770 1,937,271        
      in-kind milestone payment to arrowhead pharmaceuticals
    		                                                                
      depreciation and amortization
    		18,450,000 10,840,000 9,978,000 10,455,000 9,806,000 8,719,000 8,744,000 11,372,000 10,928,000 10,792,000 11,305,000 10,553,000 10,703,000 9,889,000 10,719,000 10,145,000 10,495,000 8,447,000 8,930,000 7,288,000 6,619,000 6,475,000 6,529,000 8,206,000 8,277,000 7,694,000 6,370,000 3,527,000 3,593,000 2,873,000 2,252,000 2,124,000 2,559,000 1,772,000 1,637,000 1,664,000 1,074,000 1,476,000 1,397,000 1,364,000 1,312,000 1,291,000 1,280,000 1,158,000 1,049,000 960,000 523,000 22,249,000 451,000 20,880,000 353,000 -18,894,000 19,384,000 347,000 217,496 479,630 525,141 484,038 428,274 -4,903,656 333,186 4,292,464 3,706,574 3,563,080 
      loss on investment in arrowhead pharmaceuticals
    		                                                                
      non-cash write-off of prepaid deposits
    		                                                                
      reduction in the carrying amounts of the right of use assets
    		3,370,000 4,022,000 3,934,000 3,878,000 4,325,000 4,012,000 3,952,000 3,859,000 3,825,000 3,593,000 3,218,000 3,553,000 3,668,000 1,859,000 3,655,000 1,213,000 4,089,000 3,803,000 2,220,000  3,360,000 3,236,000 2,153,000                                          
      change in the fair value of derivatives
    		                                                                
      accretion of investment discount
    		-1,133,000 -1,866,000 -1,912,000 -6,803,000 -10,615,000 -10,458,000 -12,401,000 -13,329,000 -12,602,000 -11,594,000 -8,651,000                                                      
      termination charges
    		                                                                
      other
    		1,136,000 1,611,000 1,692,000 308,000 2,889,000 -1,396,000 329,000 -1,487,000 2,001,000 -2,441,000 1,964,000 -5,785,000 -2,867,000 -2,829,000 1,838,000 3,656,000 178,000 1,012,000 2,774,000 -545,000 875,000 581,000 -1,381,000 -202,000 0                                        
      changes in operating assets and liabilities, net:
    		                                                                
      decrease (increase) in accounts receivable
    		                                                                
      decrease (increase) in manufacturing-related deposits and prepaids
    		-1,797,000 -2,267,000 71,136,000                                                              
      increase in inventory
    		-83,020,000 -59,189,000 -177,359,000 -161,659,000                                                             
      increase in other assets
    		-62,812,000 -22,191,000 -15,067,000 29,704,000                                                             
      increase in deferred revenue
    		                                                                
      decrease in accounts payable, accrued expenses, lease liabilities and other liabilities
    		-103,173,000 -24,467,000 -17,707,000                                                              
      net cash from operating activities
    		-14,585,000 261,337,000 -583,437,000 92,046,000 -70,699,000 14,942,000 -242,076,000 -54,657,000 -114,706,000 -122,234,000 -209,396,000 -92,392,000 -64,964,000 -66,815,000 -101,175,000 -29,326,000 -124,329,000 -109,146,000 -180,371,000 -174,535,000 -238,186,000 -107,603,000 627,790,000  -67,431,000 -79,004,000 -146,233,000  -113,318,000 -117,254,000 -35,668,000  -57,903,000 -85,147,000 -57,888,000  -60,615,000 -43,284,000 -60,688,000    -43,348,000 -25,449,000 -35,321,000 -39,504,000 -28,265,000 -277,730,000 -14,993,000 -237,372,000 -9,049,000 206,093,000 -216,601,000           -38,669,218 
      capex
    		-22,934,000 -31,796,000 -43,651,000 -38,082,000 -37,263,000 -29,167,000 -32,444,000 -19,039,000 -29,673,000 -17,909,000 -9,485,000 -7,964,000 -8,231,000 -9,078,000 -5,551,000 -2,206,000 -9,241,000 -5,894,000 -21,149,000 -28,610,000 -25,303,000 -19,169,000 -9,120,000  -9,429,000 -16,682,000 -16,263,000  -20,091,000 -8,697,000 -12,166,000  -765,000 -2,871,000 -4,465,000  -840,000 -419,000 -1,168,000    -532,000 -3,139,000 -12,464,000 -4,515,000 -5,326,000 -20,595,000 -9,000 -19,879,000 -9,000 18,252,000 -18,928,000           -4,814,759 
      free cash flows
    		-37,519,000 229,541,000 -627,088,000 53,964,000 -107,962,000 -14,225,000 -274,520,000 -73,696,000 -144,379,000 -140,143,000 -218,881,000 -100,356,000 -73,195,000 -75,893,000 -106,726,000 -31,532,000 -133,570,000 -115,040,000 -201,520,000 -203,145,000 -263,489,000 -126,772,000 618,670,000  -76,860,000 -95,686,000 -162,496,000  -133,409,000 -125,951,000 -47,834,000  -58,668,000 -88,018,000 -62,353,000  -61,455,000 -43,703,000 -61,856,000    -43,880,000 -28,588,000 -47,785,000 -44,019,000 -33,591,000 -298,325,000 -15,002,000 -257,251,000 -9,058,000 224,345,000 -235,529,000           -43,483,977 
      cash flows from investing activities:
    		                                                                
      purchase of property and equipment
    		-22,934,000 -31,796,000 -43,651,000 -38,082,000 -37,263,000 -29,167,000 -32,444,000 -19,039,000 -29,673,000 -17,909,000 -9,485,000 -7,964,000 -8,231,000 -9,078,000 -5,551,000 -2,206,000 -9,241,000 -5,894,000 -21,149,000 -28,610,000 -25,303,000 -19,169,000 -9,120,000 -17,257,000 -9,429,000 -16,682,000 -16,263,000 -20,203,000 -20,091,000 -8,697,000 -12,166,000 -3,899,000 -765,000 -2,871,000 -4,465,000 -2,914,000 -840,000 -419,000 -1,168,000 -1,085,000 -1,147,000 -637,000 -532,000 -3,139,000 -12,464,000 -4,515,000 -5,326,000 -20,595,000 -9,000 -19,879,000 -9,000 18,252,000 -18,928,000           -4,814,759 
      purchase of available-for-sale securities
    		0 0 -44,658,000 -162,911,000 -389,402,000 -330,832,000 -216,450,000 -569,536,000 -645,605,000 -403,036,000 -426,763,000 -427,540,000 -371,714,000 -357,832,000 -779,770,000 0 1,000 0 -29,989,000 -435,877,000 -140,953,000 -391,301,000 -365,437,000 -209,407,000 -252,937,000 -236,807,000 -494,481,000 -520,216,000 -355,564,000 -204,309,000 -91,514,000 -489,172,000 0       -112,369,000 -1,000   -2,179,000 -45,573,000 -49,947,000 -176,669,000                  
      maturity and sales of available-for-sale securities
    		86,551,000 68,626,000 40,758,000    477,690,000                                                          
      purchase of intangible assets and other
    		-5,312,000 -188,000 -2,238,000                                                              
      acquisition of strategic investments
    		0                                                                
      proceeds from sale of investment in arrowhead pharmaceuticals
    		                                                                
      net cash from investing activities
    		232,400,000 32,211,000 -291,177,000 764,118,000 -128,825,000 -98,528,000 218,796,000 -64,358,000 -210,571,000 96,634,000 12,492,000 9,796,000 19,119,000 -289,991,000 -785,807,000 -2,577,000 20,265,000 321,059,000 156,666,000 -123,891,000 54,075,000 -34,225,000 -17,680,000  -17,959,000 152,373,000 135,231,000 -237,736,000 -63,400,000 -55,092,000 -14,260,000 -493,695,000 124,949,000 -20,054,000 209,985,000 -198,774,000 10,224,000 78,935,000 19,422,000 -69,819,000 31,019,000 3,383,000 43,827,000 46,677,000 -20,541,000 -2,877,000 -182,289,000 -28,996,000 -7,720,000 -27,452,000 -262,000 23,859,000 -25,060,000   299,732     3,108,743   -8,641,093 
      cash flows from financing activities:
    		                                                                
      proceeds from exercise of stock options and purchase of stock under the employee stock purchase program
    		1,214,000 1,500,000 15,681,000 3,710,000 13,757,000 39,918,000 22,140,000 1,943,000 15,405,000 5,861,000 28,037,000 11,303,000 13,411,000 339,000 4,990,000 2,148,000 5,902,000 3,526,000 9,226,000 35,826,000 18,789,000 21,860,000 7,482,000  5,181,000 7,092,000 12,299,000                                      
      repayment of 2027 notes
    		                                                                
      debt issuance costs for the exchange transaction
    		                                                                
      proceeds from issuance of common stock
    		                                                                
      common stock issuance costs
    		                                                                
      repurchases of common stock
    		0                                                                
      payments related to revolving credit facility
    		-608,000                                                                
      net cash from financing activities
    		-117,790,000 -23,817,000 12,471,000 48,991,000 13,757,000 39,918,000 22,140,000 1,943,000 15,405,000 5,861,000 101,795,000 10,749,000 216,429,000 339,000 4,990,000 549,248,000 5,902,000 3,526,000 2,893,000 326,937,000 18,789,000 17,575,000 319,022,000 256,966,000 1,733,000 6,292,000 377,563,000 521,283,000 -23,955,000 25,351,000 7,471,000 506,813,000 382,237,000 -1,174,000 206,000 7,287,000 333,712,000 38,167,000 -1,037,000 125,576,000 1,576,000 20,250,000 406,000 24,000 5,407,000 96,034,000 2,690,000 477,708,000 2,971,000 454,402,000 -20,000 -232,636,000 264,944,000    7,971,098 22,311,475 6,985,851 -88,087,728 26,152 101,657,406 69,509,268 69,312,047 
      decrease in cash, cash equivalents and restricted cash
    		100,025,000 269,731,000 -862,143,000  -185,767,000 -43,668,000 -1,140,000  -309,872,000 -19,739,000 -95,109,000    -881,992,000                                                  
      cash, cash equivalents and restricted cash:
    		                                                                
      beginning of period
    		0 0 1,118,589,000  0 0 444,009,000  0 0 985,801,000  0 0 2,125,523,000  0 0 1,511,713,000  0 0 843,645,000 0 0 0 370,829,000 0 0 0 599,827,000 0 0 0 122,556,000 0 0 0 80,304,000 0 0 0 73,551,000 0 0 0 256,965,000  187,661,000  39,904,000   48,275,000 4,643,361 20,159,201 34,597,734 16,654,829 12,524,915  10,384,963    
      end of period
    		100,025,000 269,731,000 256,446,000  -185,767,000 -43,668,000 442,869,000  -309,872,000 -19,739,000 890,692,000  170,584,000 -356,467,000 1,243,531,000  -98,162,000 215,439,000 1,490,901,000  -165,322,000 -124,253,000 1,772,777,000 110,251,000 -83,657,000 79,661,000 737,390,000 161,127,000 -200,673,000 -146,995,000 557,370,000 -17,940,000 449,283,000 -106,375,000 274,859,000 -272,720,000 283,321,000 73,818,000 38,001,000 24,485,000 -13,719,000 -4,898,000 74,436,000 21,252,000 -50,455,000 53,653,000 49,101,000 -16,679,000 167,919,000 149,674,000 30,573,000 30,905,000 23,283,000 41,438,000 3,544,559 14,964,915 36,867,301 34,356,842 8,687,362 5,994,891 7,171,723 29,885,643 -13,543,067 22,001,736 
      reconciliation of cash, cash equivalents and restricted cash:
    		                                                                
      cash and cash equivalents
    		102,479,000 269,731,000 240,867,000 905,155,000 -185,767,000 -43,668,000 427,290,000 -113,502,000 -309,997,000 -19,739,000 871,668,000 -71,847,000 170,059,000 -365,312,000 1,233,877,000 516,756,000 -98,162,000 215,439,000 1,481,836,000 28,011,000 -165,322,000 -124,253,000 1,764,212,000 110,251,000 -83,762,000 76,401,000 732,190,000 161,127,000 -200,673,000                                    
      restricted cash in other assets
    		-2,454,000 0 15,579,000 0 0 0 15,579,000 -3,570,000 125,000 0 19,024,000 0 525,000 8,845,000 9,654,000 589,000 0 0 9,065,000 500,000 0 0 8,565,000 0 105,000 3,260,000 5,200,000                                      
      total cash, cash equivalents and restricted cash
    		100,025,000 269,731,000 256,446,000 905,155,000 -185,767,000 -43,668,000 442,869,000 -117,072,000 -309,872,000 -19,739,000 890,692,000 -71,847,000 170,584,000 -356,467,000 1,243,531,000 517,345,000 -98,162,000 215,439,000 1,490,901,000 28,511,000 -165,322,000 -124,253,000 1,772,777,000 110,251,000 -83,657,000 79,661,000 737,390,000 161,127,000 -200,673,000                                    
      supplemental disclosure of cash flow information:
    		                                                                
      cash paid during the period for income taxes
    		1,156,000 19,258,000 835,000 10,973,000 3,624,000 7,081,000 909,000 5,512,000                                                         
      cash paid during the period for interest
    		6,774,000 0 7,188,000 687,000 7,188,000 793,000 7,188,000 794,000 7,312,000 794,000 7,023,000 3,145,000 13,493,000 16,092,000 11,688,000 16,222,000 11,947,000 16,092,000 11,688,000 13,956,000 5,430,000 9,647,000 5,385,000 4,275,000 0   4,447,000 803,000 5,205,000 853,000 988,000 386,000 247,000 291,000 363,000 371,000 419,000 409,000 410,000 322,000 19,000 18,000  20,000 20,000 20,000  22,000                
      supplemental schedule of non-cash activities:
    		                                                                
      accrued debt issuance costs for the exchange transaction
    		                                                                
      accrued common stock issuance costs
    		                                                                
      intangible assets and property and equipment included in accounts payable and accrued expenses
    		-20,769,000 -2,759,000 29,225,000 8,899,000 3,358,000 7,554,000 22,929,000 17,280,000 -4,869,000 9,792,000 11,136,000 1,254,000 -240,000 1,336,000 4,415,000 -482,000 -3,116,000                                                
      lease liabilities arising from obtaining right of use assets
    		0 0 5,232,000 14,994,000 18,349,000 1,743,000 275,000 357,000 3,971,000 75,595,000 280,000 27,725,000 874,000 7,301,000 4,106,000 77,000 2,566,000 9,681,000 901,000 21,680,000                                             
      capitalized stock-based compensation and depreciation as inventory
    		4,043,000 6,925,000 7,285,000 7,813,000 7,449,000 6,954,000 6,333,000                                                          
      issuance of 2030 notes in exchange for 2027 notes
    		                                                                
      settlement of non-cash component of 2027 notes
    		                                                                
      common stock issued for conversion or exchange of 2027 notes
    		                                                                
      common stock issued for conversion or exchange of 2024 notes
    		   91,572,000 1,000                                                            
      modification of 2017 capped calls
    		                                                                
      gain on strategic investments
    		 -36,721,000 90,728,000                                                              
      non-cash change in the fair value of derivatives
    		   -727,000                                                             
      decrease in accounts receivable
    		                                                                
      decrease in deferred revenue
    		 25,572,000 -85,397,000 3,255,000                                                             
      increase in accounts receivable
    		  -57,383,000 -167,464,000                                                             
      acquisition of strategic investment
    		  -241,388,000                                                              
      payments related to obtaining revolving credit facility
    		  -3,210,000                                                              
      non-cash interest expense
    		   1,204,000 1,246,000   1,237,000 1,231,000   1,525,000 2,039,000 2,031,000 1,957,000 1,964,000 1,926,000 1,875,000 1,816,000 6,922,000 6,315,000 5,875,000 6,342,000 5,557,000 5,374,000 5,305,000 5,208,000 4,984,000 5,248,000 5,018,000 4,940,000             -19,000                     
      non-cash termination charges
    		   0                                                             
      impairment of strategic investments
    		                                                                
      gain from sale of priority review voucher
    		       0 0              -108,069,000         0 0 0 -125,000,000                              
      increase in manufacturing-related deposits and prepaids
    		   46,956,000                                                             
      increase in accounts payable, accrued expenses, lease liabilities and other liabilities
    		                                                                
      purchase of intangible assets
    		   0 0 0 -10,000,000 0                -1,034,000 -594,000 -599,000 -855,000 -555,000 -1,077,000 -883,000 -673,000 -624,000 -6,990,000 -356,000 -1,245,000                              
      proceeds from sale of priority review voucher
    		       0 0                       0 0 0 125,000,000                              
      settlement of capped call share options for 2024 notes
    		                                                                
      payment on maturity of 2024 notes
    		                                                                
      debt conversion costs for 2024 notes
    		       0 0 0 -6,887,000                                                      
      proceeds from 2027 notes offering, net of commissions
    		           0                                                     
      purchase of capped call share options for 2027 notes
    		           0                                                     
      debt issuance costs for 2027 notes
    		           -554,000                                                     
      repurchase of 2024 notes
    		           0                                                     
      repayment of principal amount due under 2019 term loan
    		           0                                                     
      payment on debt extinguishment of 2019 term loan
    		           0                                                     
      increase in cash and cash equivalents
    		                           161,127,000 -200,673,000 -146,995,000 -42,457,000  449,283,000 -106,375,000 152,303,000 -272,720,000 283,321,000 73,818,000 -42,303,000    885,000 21,252,000   -207,864,000 170,982,000 -19,742,000 189,578,000 -9,331,000 -2,684,000 23,283,000    2,269,567 17,702,013  -4,390,072  29,885,643  22,001,736 
      beginning of year
    		                                                                
      end of year
    		                                                                
      lease liabilities terminated
    		           0 0   20,166,000 0 0 19,967,000                                              
      maturity and sale of available-for-sale securities
    		    297,840,000     415,624,000 448,834,000  399,571,000    30,000,000 226,000,000 210,000,000  221,000,000 376,980,000 250,000,000  245,001,000 579,017,000 646,830,000    90,093,000  132,704,000                                
      partial settlement of capped call share options for 2024 notes
    		       0 0 0 80,645,000 0                                                     
      proceeds from exercise of stock options not yet received
    		                                                                
      adjustments to reconcile net income to cash flows from operating activities:
    		                                                                
      non-cash change in the fair value of contingent consideration
    		     0 10,100,000                                                          
      net decrease (increase) in accounts receivable
    		     18,809,000 21,521,000                                     946,000                     
      net increase in manufacturing-related deposits and prepaids
    		     -58,298,000 -145,046,000                                                          
      net increase in inventory
    		     -102,460,000 -60,512,000 -94,104,000 -26,612,000 -26,692,000 -306,000 -8,880,000 -26,536,000 -10,677,000 -4,687,000 -27,264,000 -19,713,000 -28,423,000 -8,372,000 -11,843,000 -40,468,000 -6,482,000 -1,789,000 -5,019,000 -9,791,000 -16,102,000 -15,022,000 -9,629,000 -11,690,000 -4,751,000 -15,770,000  -22,939,000 -11,309,000 -17,632,000                              
      net decrease in other assets
    		        -6,004,000    3,477,000 17,520,000 13,401,000                4,672,000                                  
      net decrease in deferred revenue
    		     10,036,000 -50,416,000 -20,078,000 -22,495,000 -22,250,000 -22,005,000  -22,495,000 -22,250,000 -22,005,000                                                  
      net decrease in accounts payable, accrued expenses, lease liabilities and other liabilities
    		     77,593,000 -92,843,000    -67,541,000    -5,022,000                                                  
      net increase in other assets
    		      -2,315,000    -29,996,000         -52,201,000 -69,818,000 -16,343,000 -27,966,000 -7,381,000 -7,002,000 -8,144,000 -79,564,000 -52,294,000 -54,478,000    1,966,000    -7,809,000 2,786,000 -3,180,000     -4,845,000                     
      common stock issued for exchange of 2024 notes
    		        0 0 693,377,000                                                      
      adjustments to reconcile net income to cash flows in operating activities:
    		                                                                
      net increase in accounts receivable
    		       -81,472,000 -82,047,000 -12,972,000 -9,208,000 -13,119,000 2,345,000 -25,660,000 -25,204,000 -3,203,000 -22,267,000 -9,317,000 -16,863,000 20,487,000 -17,799,000 2,847,000 -15,996,000 -22,847,000 -11,051,000 -6,471,000 -1,466,000 -443,000 -5,616,000 -3,137,000 -10,380,000  -6,960,000 -5,513,000 -7,050,000  -4,000 8,000 -13,000 -1,244,000                         
      net increase in accounts payable, accrued expenses, lease liabilities and other liabilities
    		       61,088,000 -17,554,000   12,878,000 53,195,000                                                    
      taxes paid related to net share settlement of equity awards
    		               -1,432,000 0 0 -6,333,000 0 0 0 -4,798,000 0 -3,448,000                                        
      proceeds from sales of common stock, net of offering costs
    		                               0                                 
      impairment of equity investments
    		                                                                
      maturity of available-for-sale securities
    		                                  80,000,000    21,000,000 44,085,000 43,204,000   48,314,000 37,930,000                    
      supplemental schedule of non-cash investing and financing activities:
    		                                                                
      accrued debt issuance costs for 2027 notes
    		                                                                
      loss on disposal of assets
    		           5,314,000 86,000              88,000 3,844,000 57,000 27,000 10,000 13,000                 196,000 2,454,000 65,000 -2,063,000 2,107,000 189,000 -53,059 53,498 164,253 1,028       
      supplemental schedule of non-cash investing activities and financing activities:
    		                                                                
      (gain) loss on contingent consideration
    		               0                                                 
      gain from sale of priority review voucher, net of commission
    		               0 0    0                                            
      impairment of equity investment
    		               0                                                 
      net decrease (increase) in other assets
    		               29,048,000 485,000 38,755,000 34,915,000                774,000     5,286,000 1,268,000 1,282,000 7,413,000                      
      net increase in deferred revenue
    		               -22,494,000 -22,495,000 -22,250,000 -22,005,000 -22,494,000 -22,561,000 -25,953,000 820,437,000                                          
      proceeds from sale of priority review voucher, net of commission
    		               0 0    0 0 108,069,000                                          
      proceeds from 2019 term loan
    		                                                                
      debt issuance costs for 2019 term loan
    		                                                                
      proceeds from issuance of common stock to roche, net of offering costs
    		                   0 0                                            
      shares withheld for tax included in accrued expenses
    		                0                                                
      accrued debt issuance costs
    		                                                                
      gain on contingent consideration
    		                                                                
      increase in cash, cash equivalents and restricted cash
    		            170,584,000    -98,162,000 215,439,000 -20,812,000  -165,322,000 -124,253,000 929,132,000  -83,657,000 79,661,000 366,561,000                                      
      acquired in-process research and development
    		                       0 0                         29,461,000 0  29,461,000         19,545,028  19,545,028 
      non-cash up-front payment to stridebio
    		                                                                
      acquisition of myonexus therapeutics, inc., net of cash acquired
    		                       0 0                                        
      proceeds from term loans
    		                                                                
      debt issuance costs
    		                                                                
      net increase in accounts payable, accrued expenses and other liabilities
    		                -52,956,000    20,065,000 46,009,000 -57,718,000                     15,269,000   1,704,000                  
      amortization of investment discount
    		                 -19,000 -82,000 -80,000 -178,000 -644,000 -1,284,000 -996,000 -1,649,000 -2,324,000 -3,476,000  -1,914,000 -1,569,000 -1,259,000                                  
      net decrease in accounts payable, accrued expenses and other liabilities
    		                  -44,962,000                                              
      intangible assets and property and equipment included in accrued expenses
    		                  5,729,000 -3,141,000 -740,000 2,878,000 6,154,000                                          
      issuance costs related to the roche collaboration in accrued expenses
    		                      4,285,000                                          
      loss on contingent consideration
    		                   0                                             
      reduction in the carry amounts of the right of use assets
    		                                                                
      income from debt extinguishment
    		                                                                
      repayment of july 2017 term loan
    		                                                                
      proceeds from revolving line of credit
    		                           18,150,000 44,368,000 77,119,000 96,235,000 15,708,000                                 
      repayment of revolving line of credit
    		                           -17,323,000                                     
      payment for debt extinguishment
    		                                                                
      repayment of mortgage loans and notes payable
    		                                                                
      reclassification of long term investments to short term investments
    		                           0 0 0 9,980,000                                  
      proceeds from sale of common stock, net of offering costs
    		                        0 89,000 365,264,000                                      
      right of use asset and lease liability additions
    		                                                                
      sale of available-for-sale securities included in investment receivable
    		                         -22,300,000 42,300,000                                      
      proceeds from issuance of common stock to roche
    		                      316,338,000                                          
      manufacturing right of use asset additions
    		                      27,554,000                                          
      manufacturing lease liability additions
    		                      24,783,000                                          
      net cash from operations
    		                                       -31,272,000 -46,314,000                        
      purchase of restricted investment
    		                                                                
      maturity of restricted investment
    		                               0 0 0 10,695,000                              
      net cash provided (used) in investing activities
    		                                                                
      proceeds from exercise of options and employee stock purchase program
    		                                                                
      proceeds from december 2019 term loan
    		                                                                
      repayment of june 2015 and july 2017 term loan
    		                           0                                     
      proceeds from july 2017 term loan
    		                                                                
      purchase of capped call options
    		                                                                
      proceeds from convertible debt offering
    		                                                                
      accrued debt discount and issuance costs
    		                                                                
      property and equipment included in accrued expenses
    		                       -936,000 -785,000 24,000 2,878,000 2,906,000 2,226,000 -2,691,000 2,980,000 2,140,000   330,000   80,000 19,000 107,000   45,000 -888,000 743,000                    
      net increase in accounts payable, accrued expenses, deferred revenue and other liabilities
    		                        54,100,000   58,578,000 14,069,000 12,811,000 4,704,000           4,518,000 -5,084,000                      
      purchases of restricted investment
    		                            0                                    
      repayments on mortgage loans
    		                                                                
      payment of debt extinguishment
    		                                                                
      reclassification of revolving line of credit balance to other receivable
    		                                                                
      intangible assets included in accrued expenses
    		                        -16,000 -4,000 230,000 140,000 -60,000 92,000 202,000 85,000 -7,000 86,000 179,000 -67,000                             
      accrual for debt issuance costs related to the term loans
    		                                                                
      net decrease in accounts payable, accrued expenses, deferred revenue and other liabilities
    		                          2,133,000        -886,000    -6,214,000                          
      shares withheld for taxes
    		                          889,000 8,000 3,303,000   436,000 1,482,000 144,000 165,000 213,000 1,851,000 60,000 44,000                          
      amortization of investment (discount) premium
    		                                                                
      income from extinguishment of debt
    		                                                                
      non-cash restructuring expense
    		                                                                
      accrued exit and legal fees for debts
    		                                                                
      reclassification of software licenses
    		                               0                                 
      property and equipment reclassified to asset held for sale
    		                               0                                 
      proceeds from july 2017 term loan, net of cash debt issuance costs
    		                                                                
      asset held for sale
    		                                                                
      debt issuance costs related to the term loans included in accrued expenses
    		                                                                
      offering costs related to equity offerings included in accrued expenses
    		                                                                
      payments on mortgage loans
    		                             0 -1,265,000                                  
      payments on revolving line of credit
    		                             -73,511,000 -100,142,000                                  
      proceeds from exercise of options and purchase of stock under the employee stock purchase program
    		                             21,743,000 12,643,000  7,693,000 1,337,000 2,749,000    1,488,000                          
      repayments of long-term debt
    		                                         -24,000 -25,000 -24,000 -23,000 -24,000 -23,000 -452,000 -22,000 -366,000 -21,000 244,000 -284,000            
      payment of term loan
    		                                                                
      (accretion of discount) amortization of premium on available-for-sale securities
    		                                                                
      increase in accounts payable, accrued expenses, deferred revenue and other liabilities
    		                                                                
      proceeds from term loan
    		                                                                
      payments of term loan and notes payable
    		                                                                
      payment of revolving line of credit
    		                                                                
      proceeds from exercise of options and warrants and employee stock purchase program
    		                                                                
      accrual for offering costs related to the equity offerings
    		                                   -169,000                             
      (accretion of discount) amortization of premium on available-for- sale securities and non-cash interest
    		                                                                
      non-cash restructuring expenses
    		                                                                
      proceeds from july 2017 term loan (defined in note 12), net of cash debt issuance costs
    		                                                                
      payments on june 2015 term loan (defined in note 12) and mortgage loans
    		                                                                
      accrual for offering costs related to equity offerings
    		                                                                
      amortization of (discount) premium on available-for-sale securities and non-cash interest
    		                                 -125,000 -18,000                              
      loss on abandonment of patents
    		                                 119,000 485,000 248,000 21,000 9,000 15,000 17,000 48,000                        
      repayments of long-term debt and notes payable
    		                                 -2,511,000 -2,543,000 -2,527,000 -2,525,000 -26,000 -2,525,000 -25,000                         
      accrual for debt issuance costs related to the senior secured term loan
    		                                 0 400,000  0                            
      accrual for senior secured term loan principal payment
    		                                                                
      accrual for offering costs related to the june 2016 equity offering
    		                                                                
      amortization of premium, net of discount, on available-for-sale securities and income from sales of available-for-sale securities
    		                                                                
      increase in warrant valuation
    		                                              3,251,000                  
      release and maturity of restricted investments
    		                                           4,000,000 0                    
      patent costs
    		                                     -358,000 -410,000 -450,000 -342,000 -249,000 -391,000 -319,000 -434,000 -334,000 -294,000 -10,653,000 -461,000 -9,915,000 -253,000 7,949,000 -8,474,000           -1,696,468 
      proceeds from borrowings, net of debt issuance costs
    		                                       0 -133,000                        
      cash and cash equivalents:
    		                                                                
      accrued debt issuance costs related to the senior secured term loan
    		                                       0                         
      issuance of common stock in satisfaction of warrants
    		                                                                
      issuance of notes payable in relation to the purchase of certain real and personal property located in andover, massachusetts
    		                                                                
      amortization of premium on available-for-sale securities, income from sale of available-for-sale securities and non-cash interest
    		                                    79,000                            
      purchase of restricted investments
    		                                       0        -90,000 -7,250,000                
      sale and maturity of available-for-sale securities
    		                                    11,389,000                            
      proceeds from sales of common stock
    		                                                                
      capitalized interest
    		                                       0 0 0 99,000 101,000                     
      proceeds from exercise of options, purchase of stock under the employee stock purchase program and sales of common stock
    		                                                                
      patent costs included in accrued expenses
    		                                     67,000 192,000 230,000 -65,000 70,000 100,000                      
      amortization of premium on available-for-sale securities and non-cash interest
    		                                      242,000                          
      amortization of premium on available-for-sale securities
    		                                           615,000 690,000 608,000 519,000                  
      non-cash interest
    		                                                                
      proceeds from exercise of options and warrants and the sale of common stock, net of offering costs
    		                                       125,601,000 4,233,000   48,000 5,430,000                    
      other financing activities
    		                                               -434,000                 
      tenant improvement paid by landlord
    		                                                                
      issuance of note payable in relation to the purchase of certain real and personal property located in andover, massachusetts
    		                                                                
      decrease in cash and cash equivalents
    		                                        -13,719,000                        
      accrued legal and other fees for the october 9, 2015 common stock offering
    		                                                                
      amortization of premium on available-for-sale securities and noncash interest
    		                                                                
      issuance of common stock in satisfaction of warrants and other liabilities
    		                                           0 5,570,000 3,171,000 3,044,000  1,022,000                
      accrual for the debt issuance costs related to the senior secured term loan
    		                                                                
      adjustments to reconcile net income to net cash flows used in operating activities:
    		                                                                
      amortization of premium on available-for-sale securities and other non-cash interest expense
    		                                          315,000                      
      loss on abandonment of patents and disposal of property and equipment
    		                                          131,000 76,000   6,000                  
      sale of available-for-sale securities
    		                                          44,750,000                      
      proceeds from exercise of options and warrants
    		                                          431,000                      
      supplemental disclosure of cash flow information
    		                                                                
      supplemental schedule of noncash investing activities and financing activities:
    		                                                                
      tenant improvements paid by landlord
    		                                           -1,000 89,000 -528,000 593,000 2,522,000                 
      loss on change in warrant valuation
    		                                           0 -4,256,000                    
      cash paid during the year for interest
    		                                                 510,000 22,000 -377,000 422,000 19,000           
      issuance of debt in relation to the purchase of certain real and personal property located in andover, massachusetts
    		                                                                
      net increase in accounts receivable and other assets
    		                                             -10,620,000 -10,337,000  -1,178,000                
      receivable for warrants exercised
    		                                                                
      realized gain on sale of available-for-sale securities
    		                                                                
      write-down of available-for-sale securities
    		                                                                
      impairment charge on real estate owned
    		                                                 1,445,000 0  1,336,000            
      acquisition costs
    		                                                 -2,389,000 0  -2,389,000           -2,377,616 
      proceeds from exercise of options and warrants and the sale of common stock, warrants, and partnership units, net of offering costs
    		                                              2,713,000                  
      available-for-sale securities received in connection with the private offering
    		                                                                
      property and equipment included in accounts payable and other liabilities
    		                                              3,533,000                  
      issuance of common stock for building purchase
    		                                                 750,000 0  750,000            
      assumption of long-term debt for building purchase
    		                                                 2,200,000 0  2,200,000            
      issuance of common stock to acquire assets
    		                                                                
      assumption of liabilities to acquire assets
    		                                                 2,124,000               
      realized gain on sale of short-term securities—available-for-sale
    		                                                    -3,863,000            
      write-down of short-term securities—available-for-sale
    		                                                 17,001,000   17,001,000            
      increase on warrant valuation
    		                                                                
      net increase in accounts receivable, other current assets and other assets
    		                                               -5,440,000                 
      net increase in accounts payable, accrued employee compensation, and other liabilities
    		                                               20,014,000 -955,000   -1,229,000 11,326,000   1,195,910         
      purchase of marketable securities
    		                                                 -112,993,000 0  -112,993,000            
      sale of marketable securities
    		                                                 117,724,000 0  117,724,000   909,694 902,117 3,346,336 10,346,335 -5,463,808 4,989,198 2,696,377   
      proceeds from exercise of options and warrants, and the sale of common stock, warrants, and partnership units, net of offering costs
    		                                                                
      short-term securities—available-for-sale received in connection with the private offering
    		                                                 17,897,000   17,897,000           17,897,000 
      loss on disposal of property and equipment
    		                                                                
      realized gain on sale of short-term securities — available-for-sale
    		                                                                
      write-down of short-term securities — available-for-sale
    		                                                                
      increase on warrant liability
    		                                                  10,926,000              
      changes in operating assets and liabilities:
    		                                                                
      proceeds from sale of common stock, warrants, and partnership units, net of offering costs, and exercise of options and warrants
    		                                                2,993,000 455,154,000 1,000 -233,266,000 265,614,000    7,971,098 22,311,475 6,985,851 -88,473,165 26,152 102,042,843 69,894,705 69,697,484 
      cash paid for interest
    		                                                                
      short-term securities — available-for-sale received in connection with the private offering
    		                                                                
      issuance of common stock in satisfaction of warrant liabilities
    		                                                                
      increase in warrant liability
    		                                                26,906,000                
      short-term securities — available-for-sale received in connection with private offerings
    		                                                                
      issuance of common stock and warrants in satisfaction of liabilities
    		                                                  0 -544,000 1,188,000            
      realized gain on sale of short-term securities— available-for-sale
    		                                                                
      conversion of interest accrued to common stock
    		                                                  0  8,000         7,860  7,860 
      (increase) in accounts receivable, other current assets and other assets
    		                                                  -1,830,000              
      increase in accounts payable, accrued employee compensation, and other liabilities
    		                                                  -1,567,000              
      buyback of common stock pursuant to rescission offering
    		                                                  0  -289,000           -288,795 
      withdrawal of partnership net assets
    		                                                  0  -177,000           -176,642 
      issuance of convertible debt
    		                                                  0  80,000         80,000  80,000 
      issuance of common stock to acuire assets
    		                                                                
      realized gain on sale of short-term securities - available-for-sale
    		                                                  0              
      write-down of short-term securities - available-for-sale
    		                                                  0              
      short-term securities - available-for-sale received in connection with the private offering
    		                                                  0              
      issuance of common stock for ercole assets
    		                                                  0  8,075,000            
      assumption of liabilities for ercole assets
    		                                                  0  2,124,000            
      realized gain on sale of short-term securities–available-for-sale
    		                                                                
      write-down of short-term securities–available-for-sale
    		                                                                
      supplemental disclosure of cash flow
    		                                                                
      information:
    		                                                                
      short-term securities–available-for-sale received in connection with the private offering
    		                                                                
      increase in:
    		                                                                
      accounts receivable and other current assets
    		                                                        281,612        
      change in unrealized gain on short-term securities—available-for-sale
    		                                                       -2,041 1,890 132,641   -376,173    
      (gain) loss on warrant liability
    		                                                    778,000            
      increase in accounts receivable, other current assets and other assets
    		                                                    -15,337,000            
      write-down of short-term securities —available-for-sale
    		                                                                
      accounts receivable, other current assets, and other assets
    		                                                     334,000           
      net increase in accounts payable, accrued employee compensation, deferred revenue, and other liabilities
    		                                                     85,000           
      short-term securities —available-for-sale received in connection with the private offering
    		                                                                
      issuance of common stock and warrants to vendors
    		                                                                
      compensation expense on issuance of common stock and partnership units
    		                                                             371,992  251,992 
      other assets
    		                                                        2,900       -29,847 
      investment in other lt assets
    		                                                                
      issuance of common stock and warrants in satisfaction of employee bonuses
    		                                                                
      compensation expense to non-employees on issuance of options and warrants to purchase common stock or partnership units
    		                                                      -195,802 312,637 525,126        
      gain on warrant liability
    		                                                                
      decrease (increase) in:
    		                                                                
      short-term securities—available-for-sale received in
    		                                                                
      connection with the private offering
    		                                                                
      change in unrealized gain on short-term
    		                                                                
      securities—available-for-sale
    		                                                                
      issuance of common stock to vendors
    		                                                       300,000 700,000        
      issuance of common stock and warrants for services
    		                                                        175,000     370,000 -120,000 240,000 
      compensation expense on issuance of options and warrants to purchase common stock or partnership units
    		                                                         206,329 332,890 -359,147  682,353  562,353 
      related party receivables and other current assets
    		                                                         399,958 43,738  239,677    
      net increase in accounts payable and accrued employee compensation
    		                                                         28,316    4,839,853   
      write-down of short-term securities-available-for-sale
    		                                                             12,523,088   
      other current assets
    		                                                               -738,192 
      change in unrealized loss on short-term securities– available-for-sale
    		                                                          -128,874      
      change in unrealized gain on short-term securities-available-for-sale
    		                                                                
      realized gain on sale of short-term securities
    		                                                                
      compensation expense on issuance of common
    		                                                                
      stock and partnership units
    		                                                                
      accounts payable and accrued employee compensation
    		                                                                
      short-term securities—available-for-sale received in connection with the private offering, related party
    		                                                                
      realized gain on sale of short-term investments — available for sale
    		                                                                
      proceeds from sale or redemption of short-term investments
    		                                                             247,750  247,750 
      supplemental schedule of noncash investing
    		                                                                
      activities and financing activities:
    		                                                                
      short-term securities-available-for-sale received in connection with the private offering, related party
    		                                                             17,897,000   
      change in unrealized gain on short-term securities— available-for-sale
    		                                                             -2,852,652   
      realized gain on sale of short-term investments - available for sale
    		                                                               -96,750 
      short-term securities — available-for-sale received in connection with the private offering, related party
    		                                                                
      change in unrealized gain on short-term securities — available-for-sale
    		                                                                
      write-down of short-term securities--available for sale
    		                                                                
      short-term securities--available-for-sale received in connection with the private offering, related party
    		                                                                
      change in unrealized gain on short-term securities--available-for-sale
    		                                                                
      net increase in accounts payable and accrued liabilities
    		                                                               1,737,801 
      unrealized gain on short-term securities-- available-for-sale
    		                                                               -13,278,794 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.